Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-™T) Accepted by the Center for Drug Evaluation

[
Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-™T) Accepted by the Center for Drug Evaluation
[og_img]
https://www.investing.com/news/press-releases/fourth-nda-for-kelunbiotechs-trop2-adc-sacituzumab-tirumotecan-sact-accepted-by-the-center-for-drug-evaluation-93CH-4058561


Investing.com